This activity has expired. Thank you for using WebBasedCME.com. Continue to check our activities page for additional online CME offerings .

POST-TEST - BREAKING NEWS on INCRETIN-BASED THERAPIES Summary Conference Report

INSTRUCTIONS: Select the most appropriate response. To receive credit, participants must earn a score of 80% or higher.

0. Have you created an account on WebBasedCME.com? You must register and be signed in to participate and receive CME credit for this activity.

1.	Generally speaking, which of the following statements about incretin-based therapies is not true?
A:		In clinical trials, DPP-4 inhibitors reduced A1C by about 1.5%
B:		DPP-4 inhibitors are associated with less nausea than incretin mimetics
C:		Incretin mimetics and DPP-4 inhibitors are associated with weight loss
D:		Incretin mimetics and DPP-4 inhibitors are associated with a low risk of hypoglycemia

2.	GLP-1 analogs and DPP-4 inhibitors reduce ____.
A:		Both fasting plasma glucose (FPG) and postprandial glucose (PPG)
B:		FPG only
C:		PPG only
D:		PPG, but only in lean patients

3.	Which of the following is true regarding DPP-4 inhibitors?
A:		Most DPP-4 inhibitors also inhibit DPP-8 and DPP-9
B:		Nausea is the most common side effect
C:		They promote weight loss
D:		They act by enhancing circulating levels of endogenous GLP-1

4.	Which of the following statements about exenatide LAR is not true?
A:		Weight loss was about the same as for exenatide
B:		Glycemic control was better with LAR than with exenatide
C:		More patients had A1C < 7% on LAR than on exenatide
D:		More patients had nausea on LAR than on exenatide

5.	Improvements in measures of ß-cell function have been demonstrated in clinical trials for all of the following agents except ___.
A:		Exenatide
B:		Liraglutide
C:		Sitagliptin
D:		Taspoglutide

6.	Which of the following agents was shown to reduce hepatic steatosis?
A:		Alogliptin
B:		Liraglutide
C:		Saxagliptin
D:		Taspoglutide

7.	In phase 3 studies, alogliptin lowered A1C by approximately ___.
A:		0.5%-0.8%
B:		0.8%-1.2%
C:		1.2%-1.5%
D:		1.5%-2.0%

8.	In phase 3 studies, liraglutide 1.8 mg lowered A1C by approximately___ .
A:		0.5%-0.8%
B:		0.8%-1.0%
C:		1.0%-1.3%
D:		1.4%-1.8%

9.	Which of the following antidiabetic agents was not used as a comparator in the LEAD studies?
A:		Glimepiride
B:		Glyburide
C:		Insulin glargine
D:		Rosiglitazone

10.	Which of the following dosing schedules are being examined for taspoglutide?
A:		Once daily and twice daily
B:		Once daily and once weekly
C:		Once weekly and once every 2 weeks
D:		Once weekly and once monthly